A novel high-affinity inhibitor of tumor necrosis factor (TNF) is described, which is created by the fusion of the extracellular domains of TNF-binding protein 1 (TBP-1) to both the ␣ and ␤ chains of an inactive version of the heterodimeric protein hormone, human chorionic gonadotropin. The resulting molecule, termed TNF-soluble high-affinity receptor complex (SHARC), self-assembles into a heterodimeric protein containing two functional TBP-1 moieties. The TNF-SHARC is a potent inhibitor of TNF-␣ bioactivity in vitro and has a prolonged pharmacokinetic profile compared with monomeric TBP-1 in vivo. Consistent with the long half-life, the duration of action in an lipopolysaccharide-mediated proinflammatory mouse model is prolonged similarly. In a collagen-induced arthritis mouse model, this molecule demonstrates improved efficacy over monomeric TBP-1. Based on these results, we demonstrated that inactivated heterodimeric protein hormones are flexible and efficient scaffolds for the creation of soluble high-affinity receptor complexes.
Tumor necrosis factor ␣ (TNF-␣) and TNF-␤ are naturally produced proinflammatory cytokines involved in mediating a variety of immune and inflammatory processes. TNF-␣ is expressed by a wide variety of cells, whereas TNF-␤ is expressed mainly by leukocytes (Paul and Ruddle, 1988; Vilcek and Lee, 1991) . In certain disease conditions, including arthritis, psoriasis, and endometriosis, TNF has been demonstrated to play a pathological role. TNF levels are elevated in the synovium of arthritic joints (Saxne et al., 1988) and in the peritoneum of endometriotic women (Overton et al., 1996) . Antibodies capable of neutralizing TNF production and/or bioactivity are known to be efficacious in treating certain inflammatory diseases (Beutler, 1999; Feldmann, 2002) . Although structurally distinct, both forms of TNF mediate their actions through either of two types of receptor proteins known as TNFR1 (p55) and TNFR2 (p75). These receptors occur naturally as monomeric subunits on cell membranes. In addition, both p55 and p75 also exist as soluble TNFbinding proteins (TBP-1 and TBP-2, respectively) that are generated by proteolytic cleavage of the membrane versions (Nophar et al., 1990) .
The natural role of soluble TBPs has generally been postulated as negative modulators of TNF bioactivity, although some data also support a role for TBPs as stabilizers of TNF bioactivity . Under normal conditions, these shed receptors are found at serum concentrations that are up to 1000-fold higher than TNF concentrations, whereas in certain disease conditions, such as sepsis, lupus, and rheumatoid arthritis, the concentrations of TBPs can elevate to even higher levels in serum and synovial fluid (Cope et al., 1992; Heilig et al., 1992) . It is noteworthy that although both TBP-1 and TBP-2 preferentially inhibit TNF-␣ versus TNF-␤, the relative TNF-␣ selectivity of TBP-1 (177-fold) is much greater than that of TBP-2 (only 9-fold) (Terlizzese et al., 1996) . Although TNF-␣ has been postulated to be the more important form to target in rheumatoid arthritis, as evidenced by the efficacy of the purely TNF-␣-targeting antibody Remicade, it is unclear whether some increased benefit in efficacy may be afforded by targeting TNF-␤ as well. Therapeutically, soluble forms of both receptors, TBP-1 and TBP-2, have been explored as inhibitors of TNF activity for the treatment of inflammatory diseases. Etanercept, an im-munoglobulin Fc fusion molecule containing two TBP-2 domains, inhibits bioactivity of both TNF-␣ and TNF-␤ and has been demonstrated to be efficacious in patients suffering from rheumatoid arthritis and other inflammatory diseases (Mease et al., 2000; Moreland et al., 2006) . Likewise, the extracellular domain of TNFR1 (or TBP-1) has been evaluated as a clinical candidate. This molecule has been demonstrated to be active in various models in both an unfused monomeric version (D'Antonio et al., 2000) as well as in the form of an immunoglobulin Fc fusion molecule (Mori et al., 1996) .
Whereas immunoglobulin fusion molecules are increasingly used as a method to improve the half-life and avidity of binding protein moieties, it is well known that the constant region of immunoglobulins can mediate effector functions, such as antibody-dependent cell cytotoxicity and complement-dependent cytoxicity. In cases in which the ligand may be found in association with cell membranes, as TNF can be, this may result in undesired cell death. In this case, alternative and flexible scaffolds may be desired. In an effort to generate a version of soluble TBP-1 that is long-acting, potent, and lacking an immunoglobulin constant domain, we have fused TBP-1 moieties to both the ␣ and ␤ chains of a biologically inert version of the heterodimeric protein hormone, chorionic gonadotropin (hCG). Results are presented describing the biological properties of this molecule.
Materials and Methods
Cloning and Expression. Stable expression and production of TNF-SHARC in CHO cells was performed using constructs coding for amino acids Asp20-Asn180 of TBP-1 fused to either hCG-␣ (amino acids Ala1-Cys87) or hCG-␤ (amino acids Ser1-Gln145) via a flexible amino acid linker (AGAAPG ␣-chain linker; AGAG ␤-chain linker) (see Fig. 1 ), using the calcium phosphate method. The D-␣ vector used for stable CHO transfection has been described in more detail (Kelton et al., 1992) . Bioreactors were seeded with selected CHO cell pools on Asahi Hi-charge microcarriers (Cytopore 2; GE Healthcare, Piscataway, NJ) and were fed via perfusion as necessary to maintain approximately 1 ϫ 10 6 cells/ml of media volume/day with minimum essential medium ␣ (Ϫ) containing 10% dialyzed fetal bovine serum (Invitrogen, Carlsbad, CA), 2 mM l-glutamine, and 1.0 m of methotrexate. When cultures neared growth plateau (days 8 -11), growth medium was switched to ProCHO-5 medium (Lonza Walkersville, Inc., Walkersville, MD) with 4 mM L-glutamine and hypoxanthine and thymidine supplements. Expression levels of the heterodimeric TNF-SHARC protein were determined by hCG ELISA (DSL, Inc., Webster, TX).
Purification. Culture media were filtered through OptiCap (MilliGuard OptiCap XL4, 1.2 m) filters (Millipore Corporation, Bedford, MA) at a flow rate of 400 ml/min. Under constant stirring, sodium sulfate salt (Na 2 SO 4 ) was added until conductivity of the culture medium reached 95 ms. The salt-containing medium was filtered through MilliGuard OptiCap XL4 (1.2 m) and Millipak 60 (0.22 m) (Millipore Corporation), which were connected sequentially. The clarified filtrate was loaded at a flow rate of 35 ml/min onto a phenyl Sepharose Fast Flow column (GE Healthcare) (5 cm, 100-ml bed volume) that had been pre-equilibrated with 1 liter of water and 1 liter of buffer A (20 mM Tris Cl, pH 8.0, and 1 M Na 2 SO 4 ). After loading, the column was connected to an fast-performance liquid chromatography station and washed with 400 ml of buffer A at a flow rate of 30 ml/min and eluted with 400 ml of 20 mM Tris Cl, pH 8.0. Ten-milliliter fractions were collected, with fractions 16 through 38 containing TNF-SHARC being pooled. The pool from the phenyl-Sepharose chromatography was concentrated by copperimmobilized metal-affinity chromatography (Cu-IMAC). In brief, 25 ml of chelating-Sepharose FF was packed using a 3.5-cm column and charged with 200 ml of 0.1 M CuCl 2 followed by washing with 200 ml of water and equilibration with 200 ml of 20 mM Tris Cl and 0.2 M Na 2 SO 4 . The pooled phenyl-Sepharose fractions were loaded onto the Cu-IMAC column at a flow rate of 15 ml/min, and the column was washed with 90 ml of 20 mM Tris Cl, pH 8.0, and 0.2 M Na 2 SO 4 followed by an additional washing step with 90 ml of 20 mM Tris Cl, pH 8.0, and 1 mM imidazole. The TNF-SHARC protein was eluted with 50 ml of 20 mM Tris Cl, pH 8.0, 40 mM imidazole. Ten-milliliter fractions were collected during the elution, and fractions 2 through 5 were pooled and dialyzed for 24 h against 2 liters of 20 mM Tris Cl, pH 9.5, at 4°C, with one buffer exchange. The dialyzed Cu-IMAC pool was loaded onto a Mono Q column (10/100GL) (GE Healthcare) that had been pre-equilibrated with 30 ml of 20 mM Tris Cl, pH 9.5 (buffer B) at a flow rate of 3 ml/min. The column was washed with 24 ml of buffer B and step-eluted with 82% of buffer B and 18% of buffer C (20 mM Tris Cl, pH 9.5, and 200 mM NaCl) and then 100% buffer C. To concentrate the eluate for the final size exclusion chromatography step, Centriprep (50 kDa) columns (Millipore, Corporation) were pretreated by adding 10 ml of PBS, with 0.1% Triton X-100 and a 15-min spin at 2000 rpm in a table-top centrifuge (Beckman Allegra 6R; Beckman Coulter, Inc., Palo Alto, CA), followed by washing with 10 ml of PBS and a repeat spin. Pooled Mono Q fractions containing the TNF-SHARC were applied to the pretreated Centriprep, and the column was spun at 2000 rpm with the Allegra centrifuge to reduce the volume of the pool to approximately 1.5 ml. A SEC column HW55 (26/86) (Tosoh Biosciences, Montgomeryville, PA) containing approximately 456 ml of resin was pre-equilibrated with 1000 ml of water and 500 ml of PBS/300 mM NaCl at 1.5 ml/min flow rate. The concentrate of the Mono Q pool was applied to the SEC column and eluted with PBS/300 mM NaCl at 1.5 ml/min. Fractions at 0.5 through 0.8 column volumes (corresponding to fractions 9 through 15) were collected, pooled, and dialyzed against 2 liters of PBS and, if necessary, concentrated to above 3 mg/ml. Biophysical Characterization. Purified protein was evaluated by SDS-PAGE using the Invitrogen NuPAGE Bis-Tris and Tris acetate gel systems at 30 mA/gel constant current. Reduction of protein samples was performed by incubation at 70°C for 10 min in the presence of 50 mM dithiothreitol. Boiled samples were prepared by incubation for 10 min at 100°C. For purity determination by Coomassie Blue staining, the gels were loaded at 5 to 10 g of protein.
Bio-Rad Precision-Plus All Blue calibration standard was used to determine apparent molecular weight (Bio-Rad, Hercules, CA). For Western blot analysis, proteins were transferred to polyvinylidene difluoride in an Invitrogen Transfer apparatus. The Vector ABC-AP protocol was used along with antibodies BHS107 (biotinylated sheeppolyclonal anti-hCG and hCG-␤ subunit; Chromaprobe, Maryland Heights, MO), INN-hFSH-158 (mouse anti-human CG␣5; Oxford Biotech, Oxfordshire, UK), and T2065 (goat-polyclonal anti-human-TNF sRI; Sigma Chemical, St. Louis, MO). Gels and blots were scanned with a calibrated densitometer (Bio-Rad Model GS-800) and analyzed with Quantity One software (Bio-Rad). jpet.aspetjournals.org TNF Inhibition Assay. In vitro TBP activity was measured using the A549 cell assay. Human A549 lung carcinoma cells were obtained from the American Type Culture Collection (Manassas, VA) and grown in Dulbecco's modified Eagle's medium (DMEM) highglucose containing 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin/streptomycin (Invitrogen). Cells were seeded into 96-well plates at a density of 5 ϫ 10 4 cells/well in 100 l of growth medium. Cells were allowed to grow 24 h at 37°C. All samples were diluted in growth medium plus 25 g/ml cyclohexamide. For TBP-1, a 12-point 1:2 serial dilution starting from 1 ϫ 10 Ϫ7 M was prepared. The TNF-SHARC samples were prepared in dilution medium with appropriate concentrations. An equal volume of a predetermined cytotoxic concentration of TNF-␣ medium [DMEM high-glucose containing 2 ng/ml human TNF-␣ from R&D Systems, Inc. (Minneapolis, MN)] was added to each of the TBP-1 and TNF-SHARC samples. Growth medium was removed from the cells, and 100 l of the test samples was added to the appropriate wells. Each sample was assayed in triplicate. A 1:1 mixture of the dilution medium and TNF-␣ medium was added to the last three wells as blanks. After incubating overnight in a cell-culture incubator, samples were removed and the cells were washed twice with PBS. To each well was added 100 l of 4% paraformaldehyde. After 1.5 h, wells were washed twice with PBS (without magnesium and calcium). A volume of 40 l of 0.5% crystal violet in 30% methanol was added to each well and incubated for 1 h. The plate was washed twice by submerging in a beaker of water and dried. Crystal violet uptake was measured at the optical density at 540 nm (minus optical density of turbidity at 690 nm) using a SpectraMax microplate reader (Molecular Devices, Sunnyvale, CA). IC 50 was determined for TNF-SHARC based on standard four-parameter curve fitting using SoftMax Pro 2.1 software (Molecular Devices). As TBP-1 failed to achieve complete inhibition at the highest doses tested, the IC 50 was determined by assigning the maximal absorbance plateau to that determined experimentally for TNF-SHARC, because by visual inspection of the cells, it was observed that the maximal absorption values for TNF-SHARC were associated with complete inhibition of TNF-induced cytotoxicity.
hCG Bioassay. In vitro hCG activity was assessed using CHO cells stably transfected with the human luteinizing hormone (LH)/chorionic gonadotropin receptor. Growth medium for the cells was minimum essential medium ␣ supplemented with 10% fetal bovine serum, and 600 g/ml G418 (Geneticin; all from Invitrogen). Assay medium was DMEM/F12 (phenol-free) supplemented with 1 mg/ml bovine serum albumin (Sigma Chemical) and 0.1 M IBMX (3-isobutyl-1-methylxanthone phosphodiesterase inhibitor; Sigma Chemical). Cells were seeded into 96-well plates at a density of 2 ϫ 10 4 cells/well in growth medium, leaving the first two rows empty for the cAMP standards. After 24 h at 37°C in a cell-culture incubator, growth medium was removed and 25-l assay medium was added to the cells. After 15 min at 37°C, test samples diluted in assay medium were added in a volume of 20 l. A 12-point serial 1:3 dilution of hCG starting at 2.25 ϫ 10 Ϫ8 M was included as a positive control for the assay. After 1 h at 37°C, assay medium was discarded, and 60 l of assay lysis buffer from the cAMP-Screen Direct System kit (Applied Biosystems, Foster City, CA) was added. Subsequent steps for assay of cAMP production by the cells were done according to the protocol supplied in the assay kit.
Pharmacokinetics. All in vivo studies were approved by the Institutional Animal Care and Use Committees and the respective governmental regulatory authorities. Eight to 10-week-old male CD-1 mice (Charles River Laboratories, Wilmington, MA) were stratified by body weight into groups of three mice per group. Mice received a single subcutaneous injection of 30 g of TBP-1 or TNF-SHARC in 100 l of PBS and were anesthetized with isoflurane for blood sampling at either 0, 0.5, 1, 2, 4, 8, 12, 24, or 48 h. Blood samples were collected by heart puncture with heparinized needles. Plasma samples were stored at Ϫ20°C for assaying those test compounds with anti-hCG ELISA (DSL). Pharmacokinetic parameters were determined using PK Solutions software (Summit PK, Montrose, CA).
Proinflammatory Cytokine Inhibition Assay. Serum IL-6 concentrations were determined by ELISA (R&D Systems, Inc.) following collection of serum from 8-week-old C3H/Hen female mice (Elevage Janvier, Le Genest Saint Isle, France) 150 min after intraperitoneal administration of LPS (0111:B4) at 0.9 mg/kg in saline. Mice (n ϭ 6 per group) were pretreated with either TBP-1 (5 mg/kg s.c.) or TNF-SHARC (5 mg/kg s.c.) 1, 6, or 24 h before the LPS challenge.
Collagen-Induced Arthritis Model. Induction of collagen-induced arthritis in mice was performed as described previously (Plater-Zyberk and Bonnefoy, 1995; Malfait et al., 1998) . In brief, 8 to 12-week-old male DBA/1 mice (Charles River) were immunized intradermally at the tail base with a 0.2-ml emulsion of 100 g of bovine type II collagen (Morwell Diagnostics, Zurich, Switzerland) in Complete Freund's adjuvant (Difco, Detroit, MI) containing 0.4 mg of Mycobacterium tuberculosis. At approximately 3 weeks after immunization, signs of inflammation were observed affecting one or more limbs. For clinical score, each animal was scored 0 to 2 for the number of inflamed digits (0 ϭ no digits involved; 0.5 ϭ 1-5 digits; 1 ϭ 5-10 digits; 1.5 ϭ 11-15 digits, and 2 ϭ 15-18 digits). For all groups (n ϭ 8 mice per group), treatment was initiated when individual animals reached a clinical score of Ն1.5 and were treated for 7 consecutive days. Treatments included subcutaneous administration of TBP-1 (10 mg/kg in PBS) administered twice per day or TNF-SHARC (1, 3, or 10 mg/kg in PBS) administered once per day. For a positive control, one group received indomethacin p.o. at 2 mg/kg in water. Clinical score was evaluated daily, and results were analyzed by Kruskal-Wallis test followed by the pairwise Wilcox test.
Results
Biochemical Characterization of TNF-SHARC. The TNF-SHARC was designed by fusion of the nucleic acids encoding amino acids 20 to 180 of the TBP-1 protein to those coding both hCG-␣ (amino acids 1-87) and ␤ (amino acids 1-145) chains via a short peptide-linker sequence (Fig. 1) . The truncation of the c-terminal amino acids 88 to 92 of the full-length ␣ chain was included to eliminate native hCG bioactivity . The resulting TNF-SHARC protein ran as a single band with an apparent molecular mass of 87 kDa under nonreducing SDS-PAGE conditions and dissociated into subunits of 57 and 47 kDa upon heating and reduction ( Fig. 2A) . Western blot analysis confirmed that the heterodimeric nature of the TNF-SHARC as the single nonreduced band immunoreacted with antibodies to TBP-1, hCG-␣ chain, and hCG-␤ chain (Fig. 2B) . Under boiled but not reduced conditions, the 57-kDa band and, to a lesser extent, the 47-kDa band were recognized by the anti-hCG-␤-chain antibody, whereas the anti-hCG-␣-chain antibody recognized the 47-but not 57-kDa band. As we have previously observed that, under these same conditions, the anti-␣ antibody is highly selective in recognizing the ␣ chain of wildtype hCG, whereas the anti-␤ antibody recognizes wild-type hCG-␤ chain strongly with some cross-reactivity of the ␣ chain (data not shown), these data support the formation of a heterodimeric molecule created by the interaction of the TBP-1-hCG-␣ chain with the TBP-1-hCG-␤ chain. Similar to hCG itself, a significant proportion of the TNF-SHARC apparently did not form interchain disulfide bonds because boiling of the protein under nonreducing conditions was sufficient to dissociate the two subunits. Because the dissociation was not complete, it is unclear whether this was due to incomplete heat denaturation or to the possibility that some TNF-SHARC may exist as a disulfide-linked heterodimer.
In Vitro Bioactivity. Neutralization of TNF-␣ bioactivity was determined as the inhibition of TNF-mediated cytotoxicity of A549 cells. As demonstrated in Fig. 3A , on a molar basis, TNF-SHARC was significantly more potent than monomeric TBP-1 (IC 50 : 0.4 nM versus 3.1 nM, respectively) in inhibiting TNF activity. Moreover, the relatively steep inhibition curve of TNF-SHARC was consistent with an increased avidity for TNF, probably because of the bivalent nature of the molecule. To confirm that the deletion of the terminal amino acids of the hCG-␣ chain reduced hCG bioactivity, TNF-SHARC was added to human LH receptor expressing CHO cells. Whereas hCG induced cAMP with an EC 50 of 16.8 pM (n ϭ 4), TNF-SHARC failed to achieve EC 50 at over 20 M, indicating a reduction in bioactivity potency of over one million-fold (Fig. 3B) .
Pharmacokinetics and Pharmacodynamics of TNF-SHARC. After subcutaneous administration in mice, TNF-SHARC displayed a markedly prolonged pharmacokinetic profile compared with monomeric TBP-1 (Fig. 4A) . Although the maximal serum concentration for TNF-SHARC was less than 2-fold greater than that for TBP-1 (2.01 versus 1.24 g/ml, respectively), the elimination half-life was dramatically greater for TNF-SHARC (21.2 versus 1.3-3.0 h). The resulting exposure of TNF-SHARC, as measured by serum concentration area-under-the-curve, was 61.8 g h/ml compared with 6.0 g h/ml for TBP-1. To determine whether the observed prolonged serum residence time of TNF-SHARC, relative to TBP-1, corresponded to an increase in duration of biological activity in vivo, both molecules were assessed in an LPS-induced proinflammatory mouse model. In this model, duration of action was assessed by staggering the time period between the administration of the TNF inhibitor and the LPS challenge from between 1 and 24 h. As demonstrated in Fig.  4B , TBP-1 was highly effective when administered within 1 hbefore the LPS challenge but was weakly effective when LPS was administered after 6 or more hours after the TBP-1. In contrast and as predicted by the pharmacokinetic profile, TNF-SHARC was highly effective even after a period of 24 h between time of administration and LPS challenge.
TNF-SHARC Activity in Collagen-Induced Arthritis Model. To determine the efficacy of TNF-SHARC in the collagen-induced arthritis model, mice were treated with ei- . Bands were characterized using antibodies to hCG-␣ (left lanes), TBP-1 (center lanes), and hCG-␤ (right lanes). Fig. 3 . In vitro bioactivity of TNF-SHARC. A, TNF inhibitory activity was assessed by the ability to decrease TNF-␣-mediated cytopathicity of A549 cells. Inhibitory activity was determined as the IC 50 of the titration of TBP-1 and TNF-SHARC. Cell survival was determined following addition of crystal violet as the absorbance at 540 nm (minus absorbance at 690 nm). B, LH receptor agonist activity was determined as the EC 50 for cAMP production in human LH receptor-transfected CHO cells by TBP-1 and TNF-SHARC.
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iment (see Fig. 5 ). Although treatment with 1 and 3 mg/kg TNF-SHARC resulted in similar trends in reduction of clinical score, the 3 mg/kg regimen achieved significant reduction ( p Ͻ 0.05 versus vehicle control) on day 5. Treatment with 1 mg/kg dose failed to achieve significance at any time point. In contrast to TNF-SHARC, monomeric TBP-1 failed to achieve significant reduction in clinical score at any time, even when dosed at twice the total daily dose as TNF-SHARC. These results are consistent with the improved potency and pharmacokinetic properties of TNF-SHARC compared with TBP-1.
Discussion
Several examples of protein scaffolds have been reported to affect desired pharmacological characteristics for functional peptide moieties. For example, immunoglobulin constant domains have been used to fuse a variety of active ligands and binding proteins resulting in bivalent molecules with improved avidity as well as longer half-lives (reviewed in Chamow and Ashkenazi, 1996) . In addition, both growth hormone and interferon have been fused to albumin in an attempt to prolong the activity of these two normally short half-lived molecules (Osborn et al., 2002a,b) . The choice of hCG as a fusion partner in the current studies was based on several factors. In particular, the self-assembling heterodimeric nature and exposed N and C termini of the scaffold provide a flexible platform to which functional peptides can be fused. Hence, it may be possible to fuse distinct peptide moieties to the ␣ and ␤ chains, creating a multifunctional molecule. In addition, the N termini are approximately 10 Å apart so that the fusion of active peptide moieties to both chains may be sufficiently close to permit cooperativity between the binding sites, possibly leading to increased ligand avidity. This may be particularly important for soluble TNF because this ligand typically is present as a homotrimer (Smith and Baglioni, 1987; Wingfield et al., 1987) .
hCG belongs to a family of gonadotropin hormones, including follicle stimulating hormone, LH, and thyroid stimulating hormone, which share a common ␣ chain and a hormonespecific ␤ chain. A unique feature of this family is that the heterodimer is stabilized by a 20 amino acid segment of the ␤ chain that wraps around the loop 2 domain of the ␣ chain (Xing et al., 2001) . This "seatbelt" arrangement maintains the heterodimeric structure in the absence of intermolecular disulfide bonds. Studies described in the present report focused on the bioactivities of a version containing two TBP-1 moieties fused to the N termini of both hCG chains. As active molecules could be also generated when TBP-1 was fused to the C termini of both hCG chains (data not shown), it may be possible that a single molecule could be constructed that has up to four active and possibly different peptide moieties. One major obstacle of using a peptide scaffold comprising a heterodimeric protein hormone is the potential for bioactivity mediated by the scaffold itself. In this regard, the final TNF-SHARC molecule contains an hCG-␣ chain in which the terminal five amino acids had been deleted, since it has been reported that these deletions in hCG eliminate interaction with the LH receptor without disruption of the holoprotein structure . Although other strategies have been published for reducing hCG binding to LH receptors, including specific point mutations (Chen et al., 1991; , we selected the deletion strategy because it has less potential for immunogenicity than methods resulting in the alteration of the primary amino acid sequence. In our hands, the TNF-SHARC molecule containing the termi- nal ␣-chain five amino acid deletion had negligible hCG bioactivity in an LH receptor-expressing cell bioassay even when added at one million times the active concentration of hCG itself.
TNF is recognized as a mediator of pathology in certain inflammatory diseases, and selective inhibitors of TNF are efficacious in patients suffering from these conditions. Although it is clear that TNF-␣ plays a major role in this pathology, the role of TNF-␤ is less clear. Infliximab, an antibody product specific for TNF-␣, has been demonstrated to be effective in treating patients with rheumatoid arthritis (Maini et al., 1999) . Likewise, etanercept, the TBP-2-based immunoglobulin fusion molecule that inhibits both TNF-␣ and TNF-␤, is also effective in this indication. Notably, of these therapeutics, only infliximab induces remission in Crohn's disease. Both of these treatments have been associated with increased incidence of opportunistic infections in patients (Keane, 2005) . Aside from differences in TNF-␣/ TNF-␤ selectivity, another difference between these two therapeutics is the ability to bind membrane-associated TNF-␣; whereas infliximab readily binds both soluble and membrane TNF, etanercept is reported to be selective for the soluble form (Scallon et al., 2002) . In a biological sense, this may be relevant since it has been demonstrated that antibodies binding to membrane-associated TNF can initiate signal transduction (Mitoma et al., 2005) . Ultimately, it remains to be determined which TNF binding profile is optimal for greatest efficacy and least associated with adverse events. Similar to TBP-2, TBP-1 is a structurally complex protein, containing 24 cysteine residues as well as three n-glycosylation sites (Nophar et al., 1990; Jones et al., 1997) . The fact that TBP-1 is reported to be up to 10-fold more potent in inhibiting TNF cytotoxicity (Hale et al., 1995) and has greater TNF-␣ selectivity than does TBP-2 (Terlizzese et al., 1996) suggests that TBP-1-based therapeutics may have unique clinical utility. Several TBP-1-based TNF inhibitors have been explored as therapeutic candidates, including a mammalian cell-derived monomeric version (Trinchard-Lugan et al., 2001) , an immunoglobulin constant region-based fusion (Furst et al., 2003) , and a PEGylated Escherichia coli derived monomeric version (Moreland et al., 2000) . Each of these molecules has been demonstrated to be efficacious in animal models and/or patients. Like the immunoglobulin fusion approach, the TBP-1-based TNF-SHARC has two potential binding sites, but unlike the IgG fusion, the TNF-SHARC would not be expected to induce antibody or complement dependent cytotoxicity upon interaction with membrane-bound TNF.
Fusion of TBP-1 to the hCG-␣ and -␤ chains imparts a 10-fold enhancement in pharmacokinetic exposure (area-under-the-curve) in mice, even though the half-life of hCG itself is only approximately 2-fold greater than that of TBP-1 (data not shown). This synergy of half-life is probably due to the fact that the molecular mass of the TNF-SHARC holoprotein (87 kDa) may be greater than the kidney-filtration molecular mass cut-off (roughly 70 kDa) observed for other proteins (Knauf et al., 1988) , whereas those for TBP-1 and hCG are below this size. Based on this pharmacokinetic improvement, together with the increased specific activity, it is not surprising that the TNF-SHARC would demonstrate superior efficacy in the collagen-induced arthritis model compared with that of monomeric TBP-1. Perhaps more importantly, the heterodimeric nature of this scaffold suggests that inactivated hCG maybe an extremely flexible approach to designing novel biotherapeutics beyond the TBP-1 fusion.
A novel approach in the construction of a TNF antagonist has been described based on the fusion of the soluble TNF receptor TBP-1 with the N terminus of both chains of the heterodimeric hormone hCG. The resulting molecule is a potent inhibitor of TNF that has a prolonged duration of action and resulting enhanced efficacy in preclinical inflammatory models.
